BACKGROUND AND PURPOSE: In the Secondary Prevention of Small Subcortical Strokes (SPS3) trial, addition of clopidogrel to aspirin was associated with an unexpected increase in mortality in patients with lacunar strokes. We assessed the effect of the addition of clopidogrel to aspirin on mortality in a meta-analysis of published randomized trials. METHODS: Randomized trials in which clopidogrel was added to aspirin in subjects with vascular disease or vascular risk factors were identified. Trials were restricted to those with a mean follow-up of ≥14 days in which both the combination of aspirin and clopidogrel was tested and mortality was reported. RESULTS: Twelve trials included 90 934 participants (mean age, 63 years; 70% men; median follow-up, 1 year) with 6849 observed deaths. There was no significant increase in mortality with the combination therapy either in 4 short-term (14 days-3 months; OR, 0.93; 95% CI, 0.87-0.99) or in 7 long-term (>3 months; hazard ratio, 0.97; 95% CI, 0.91-1.04) trials after 1 long-term trial (the SPS3 trial) was excluded because of heterogeneity. Addition of clopidogrel was associated with an increase in fatal hemorrhage (OR, 1.35; 95% CI, 0.97-1.90) and a reduction in myocardial infarction (OR, 0.82; 95% CI, 0.74-0.91). CONCLUSIONS: The addition of clopidogrel to aspirin has no overall effect on mortality. The SPS3 trial results are outliers, possibly because of a lower prevalence of coronary artery ischemia. Addition of clopidogrel to aspirin increases fatal bleeding and reduces myocardial infarction. CLINICAL TRIAL REGISTRATION: URL: http//www.clinicaltrials.gov. Unique identifier: NCT00059306.
BACKGROUND AND PURPOSE: In the Secondary Prevention of Small Subcortical Strokes (SPS3) trial, addition of clopidogrel to aspirin was associated with an unexpected increase in mortality in patients with lacunar strokes. We assessed the effect of the addition of clopidogrel to aspirin on mortality in a meta-analysis of published randomized trials. METHODS: Randomized trials in which clopidogrel was added to aspirin in subjects with vascular disease or vascular risk factors were identified. Trials were restricted to those with a mean follow-up of ≥14 days in which both the combination of aspirin and clopidogrel was tested and mortality was reported. RESULTS: Twelve trials included 90 934 participants (mean age, 63 years; 70% men; median follow-up, 1 year) with 6849 observed deaths. There was no significant increase in mortality with the combination therapy either in 4 short-term (14 days-3 months; OR, 0.93; 95% CI, 0.87-0.99) or in 7 long-term (>3 months; hazard ratio, 0.97; 95% CI, 0.91-1.04) trials after 1 long-term trial (the SPS3 trial) was excluded because of heterogeneity. Addition of clopidogrel was associated with an increase in fatal hemorrhage (OR, 1.35; 95% CI, 0.97-1.90) and a reduction in myocardial infarction (OR, 0.82; 95% CI, 0.74-0.91). CONCLUSIONS: The addition of clopidogrel to aspirin has no overall effect on mortality. The SPS3 trial results are outliers, possibly because of a lower prevalence of coronary artery ischemia. Addition of clopidogrel to aspirin increases fatal bleeding and reduces myocardial infarction. CLINICAL TRIAL REGISTRATION: URL: http//www.clinicaltrials.gov. Unique identifier: NCT00059306.
Authors: Thomas H Wang; Deepak L Bhatt; Keith A A Fox; Steven R Steinhubl; Danielle M Brennan; Werner Hacke; Koon-Hou Mak; Thomas A Pearson; William E Boden; P Gabriel Steg; Marcus D Flather; Gilles Montalescot; Eric J Topol Journal: Eur Heart J Date: 2007-08-02 Impact factor: 29.983
Authors: Marc S Sabatine; Christopher P Cannon; C Michael Gibson; Jose L López-Sendón; Gilles Montalescot; Pierre Theroux; Marc J Claeys; Frank Cools; Karen A Hill; Allan M Skene; Carolyn H McCabe; Eugene Braunwald Journal: N Engl J Med Date: 2005-03-09 Impact factor: 91.245
Authors: Deepak L Bhatt; Keith A A Fox; Werner Hacke; Peter B Berger; Henry R Black; William E Boden; Patrice Cacoub; Eric A Cohen; Mark A Creager; J Donald Easton; Marcus D Flather; Steven M Haffner; Christian W Hamm; Graeme J Hankey; S Claiborne Johnston; Koon-Hou Mak; Jean-Louis Mas; Gilles Montalescot; Thomas A Pearson; P Gabriel Steg; Steven R Steinhubl; Michael A Weber; Danielle M Brennan; Liz Fabry-Ribaudo; Joan Booth; Eric J Topol Journal: N Engl J Med Date: 2006-03-12 Impact factor: 91.245
Authors: Ron J G Peters; Shamir R Mehta; Keith A A Fox; Feng Zhao; Basil S Lewis; Steven L Kopecky; Rafael Diaz; Patrick J Commerford; Vicent Valentin; Salim Yusuf Journal: Circulation Date: 2003-09-22 Impact factor: 29.690
Authors: S Claiborne Johnston; J Donald Easton; Mary Farrant; William Barsan; Holly Battenhouse; Robin Conwit; Catherine Dillon; Jordan Elm; Anne Lindblad; Lewis Morgenstern; Sharon N Poisson; Yuko Palesch Journal: Int J Stroke Date: 2013-08 Impact factor: 5.266
Authors: James Kennedy; Michael D Hill; Karla J Ryckborst; Michael Eliasziw; Andrew M Demchuk; Alastair M Buchan Journal: Lancet Neurol Date: 2007-10-10 Impact factor: 44.182
Authors: Mukul Sharma; Lesly A Pearce; Oscar R Benavente; David C Anderson; Stuart J Connolly; Santiago Palacio; Christopher S Coffey; Robert G Hart Journal: Stroke Date: 2014-08-26 Impact factor: 7.914
Authors: Jennifer Yeung; Benjamin E Tourdot; Reheman Adili; Abigail R Green; Cody J Freedman; Pilar Fernandez-Perez; Johnny Yu; Theodore R Holman; Michael Holinstat Journal: Arterioscler Thromb Vasc Biol Date: 2016-07-28 Impact factor: 8.311
Authors: Robert Côté; Yu Zhang; Robert G Hart; Leslie A McClure; David C Anderson; Robert L Talbert; Oscar R Benavente Journal: Neurology Date: 2014-01-02 Impact factor: 9.910
Authors: Oscar R Benavente; Robert G Hart; Leslie A McClure; Jeffrey M Szychowski; Christopher S Coffey; Lesly A Pearce Journal: N Engl J Med Date: 2012-08-30 Impact factor: 91.245
Authors: Santiago Palacio; Robert G Hart; Lesly A Pearce; David C Anderson; Mukul Sharma; Lee A Birnbaum; Oscar R Benavente Journal: Int J Stroke Date: 2013-05-22 Impact factor: 5.266